Samsung Bioepis said Sunday it is finally licensed to sell its biosimilar -- also known as follow-on biologic -- to the European market. It received the final approval from the European Commission. 
 
The company's benepali is now scheduled to have the last administrative procedure after receiving positive reviews from Committee for Medicinal Products for Human Use of European Medicines Agency in November.
 
Through the final approval, benepali is set to be available in 28 EU member nations and European Economic Area including Norway, Iceland and Liechtenstein. Benepali is etanercept biosimilar similar to Brenzys launched in December in the local market.
 
Samsung Bioepis received an approval for rheumarthritis, psoriatic arthritis and spondylarthritis.